Table 2.
Multivariate Cox analysis for PFS.
| Variable | Immunotherapy-Treated Patients | Control Patients | ||||
|---|---|---|---|---|---|---|
| HR | 95%CI | p | HR | 95%CI | p | |
| N prior systemic treatment lines > 2 | 1.77 | (0.91–3.41) | 0.09 | 0.82 | (0.47–1.45) | 0.50 |
| Age > 65 | 1.56 | (0.78–3.11) | 0.21 | 0.88 | (0.50–1.56) | 0.66 |
| Performance status > 0 | 1.04 | (0.57–1.92) | 0.89 | 1.48 | (0.91–2.42) | 0.12 |
| LIPI | 0.01 | 0.70 | ||||
| LIPI intermediate | 2.21 | (1.16–4.23) | 0.97 | (0.59–1.60) | ||
| LIPI poor | 3.89 | (1.49–10.13) | 1.34 | (0.64–2.79) | ||
| Albumin > 35 g/L | 0.63 | (0.31–1.29) | 0.20 | 0.77 | (0.46–1.29) | 0.31 |
| Myxoid liposarcoma | 3.08 | (0.85–11.13) | 0.09 | - | - | - |
| Other sarcoma histotypes | 1.02 | (0.52–2.02) | 0.95 | - | - | - |
| Synovial sarcoma | 2.53 | (0.88–7.27) | 0.09 | - | - | - |
| Genomic profile translocation related | - | - | - | 0.59 | (0.36–0.95) | 0.03 |
| Prior anthracyclines | - | - | - | 1.76 | (0.98–3.17) | 0.06 |
| Liver metastasis | - | - | - | 0.88 | (0.49–1.57) | 0.66 |
| Lung metastasis | - | - | - | 1.46 | (0.84–2.54) | 0.18 |
| Combination treatments | - | - | - | 0.59 | (0.36–0.95) | 0.03 |
| Angiosarcoma | - | - | - | 1.66 | (0.55–5.04) | 0.37 |
| Well/de-differentiated liposarcoma | - | - | - | 1.07 | (0.53–2.15) | 0.85 |
Abbreviations: 95%CI, 95% Confidence Interval; HR, hazard ratio; LIPI, lung immune prognostic index.